Literature DB >> 31418616

Endogenous Bacterial Endophthalmitis: A Five-Year Retrospective Review at a Tertiary Care Academic Center.

Thomas L Jenkins1,2, Katherine E Talcott1, Douglas R Matsunaga1,2,3, Martha E Ryan1,2,3, Anthony Obeid1, Christine A Chung2,3, Sunir J Garg1.   

Abstract

PURPOSE: To better characterize the demographics and outcomes of endogenous bacterial endophthalmitis (EBE).
METHODS: Retrospective observational case series of 49 eyes of 41 patients with EBE evaluated at a single academic center.
RESULTS: Gram stain (p = .395), symptom duration prior to treatment (p = .483), and number of intravitreal antimicrobial injections (p = .421) did not correlate with mean change in VA. There was no significant difference between mean LogMAR VA at initial evaluation (1.7 ± 0.9) and last available follow up (1.4 ± 1.1, p = .15). Patients with bilateral EBE had 7.25 times greater odds of having cancer (95% CI 1.28, 41.14; p = .025).
CONCLUSION: EBE in a North American population showed poor visual recovery despite treatment. It was most commonly due to gram-positive bacteria with the most common infectious source being endocarditis. Malignancy should be considered in patients with bilateral EBE.

Entities:  

Keywords:  Endogenous; North America; bacterial endophthalmitis; endogenous bacterial endophthalmitis; endophthalmitis

Mesh:

Year:  2019        PMID: 31418616     DOI: 10.1080/09273948.2019.1642497

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  The microbiological spectrum, antimicrobial resistance pattern, and visual outcomes of endogenous endophthalmitis in West Virginia 2009-2019.

Authors:  Chang Sup Lee; Jeffrey Desilets; Wei Fang; David M Hinkle
Journal:  Int Ophthalmol       Date:  2022-05-23       Impact factor: 2.029

2.  Klebsiella pneumoniae endogenous endophthalmitis secondary to liver abscess syndrome.

Authors:  Álvaro Fernández-Vega González; Alan R Berger; David R Chow
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.